Hetero Drugs Ltd. has introduced a cut-price generic version of Gilead Sciences Inc.’s HIV therapy Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) in India, the first such version to hit the market under a broad licensing deal provided by the US firm to a large group of local firms.
Hetero Launches India's First Generic Of Gilead’s Biktarvy
Introduces Combination Product Under Voluntary License
Hetero launches cut-price version of Gilead’s Biktarvy in India but 20 other India-based firms also hold licenses for the product. Gilead is entitled to a “modest royalty” on products produced under the voluntary license.
